Department of Medicine and Department of Epidemiology and Biostatistics, Western UniversityLondon, ON, Canada
65 - Efficacy and Safety of Icotrokinra, a Targeted Oral Peptide That Selectively Blocks IL-23 Receptor Activation, in Ulcerative Colitis: Results From Week 28 of ANTHEM-UC, a Phase 2b Dose-Ranging Trial
Wednesday, October 29, 20258:30 AM - 8:40 AM PDT
66 - Duvakitug, an anti-TL1a mAb, Demonstrates Efficacy and Favorable Safety as an Induction Treatment in Adults With Moderately to Severely Active Crohn’s Disease: Results From the RELIEVE UCCD Phase 2b Basket Trial
Wednesday, October 29, 20258:40 AM - 8:50 AM PDT